SS-31

SS-31 / elamipretide is the compound that demonstrates most clearly how good mechanism plus compelling animal data plus human clinical trials can still not equal clear therapeutic success — and how that frustrating reality does not necessarily mean the compound doesn't work. It may mean the trials were measuring the wrong things, in the wrong populations, on the wrong timescales.

The central tension resolved: SS-31 is FDA-approved (FORZINITY, Barth syndrome, September 2025) and most of its larger clinical trials failed their primary endpoints. The mechanism is the best-characterized of any mitochondrial compound in this reference — cardiolipin binding, cristae stabilization, ETC supercomplex organization, ROS reduction at source — confirmed by multiple independent research groups using biophysical, proteomic, and cellular approaches. The human ex vivo data showing ADP sensitivity restoration in aged skeletal muscle mitochondria is one of the more compelling human-tissue mechanistic confirmations in any longevity chapter. And the pattern of clinical trial failures — heart failure, mitochondrial myopathy — combined with the contested accelerated approval for Barth syndrome, places SS-31 in a genuinely uncertain position: compelling mechanism, real FDA approval, mixed clinical translation.

The strongest argument for SS-31 in anti-aging use: the mechanism is real and precisely characterized. The FDA has approved elamipretide for a mitochondrial disease where the same mechanism (cardiolipin stabilization) should operate. The human ADP sensitivity data is the most direct human-tissue evidence for the anti-aging application of any mitochondrial compound in this reference. The safety profile across all trials is excellent. No compound in this reference works more directly on the fundamental structure of energy production.

The strongest argument for caution: every clinical trial primary endpoint failed except the contested Barth syndrome accelerated approval. If the mechanism works as described, why haven't the trials produced clear clinical benefit signals? The most honest answer: endpoint selection and patient heterogeneity are extremely difficult in mitochondrial disease trials, and the trials may have failed for reasons unrelated to mechanism failure. But 'may have failed for other reasons' is not the same as 'we know it works in humans.' The community uses SS-31 at doses 4-8x below the clinical trial doses, for an application (anti-aging) that has never been studied in a controlled human trial. The dose and application are doubly unvalidated.